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INTRODUCTION 
Tuberculosis is one of the oldest human diseases. Tuberculosis 
affects almost all organs of the human body. Tuberculosis affection of the 
central nervous system is seen in 1 %  of all cases of tuberculosis. It’s a 
major extra-pulmonary manifestation of Tuberculosis.Central nervous 
Tuberculosis{CNS-TB}  is a devastating disease. It may lead to 
unacceptable increase in mortality and morbidity. Tuberculous meningitis 
is  commonly seen especially in developing countries . The key to cure the 
disease is early diagnosis and initiation of treatment. The definitive 
diagnosis requires the demonstration of acid fast bacilli via a smear or 
culture. The diagnostic yield of this test is low. And hence the exact 
diagnosis of Central nervous system  tuberculosis still remains a formidable 
challenge.  
A number of indirect methods have been used to diagnose Central 
nervous system tuberculosis . The Cerebro spinal fluid{CSF} analysis for 
concentration of protein and sugar and Cerebro spinal fluid cell count have 
been important in the diagnosis of Tuberculous meningitis. However there 
is a need of other markers  for the diagnosis of Tuberculous meningitis in 
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equivocal cases. One such marker that is widely used is Cerebro spinal 
fluid- Adenosine deaminase  level. Cerebro spinal fluid – Adenosine 
deaminase activity has been used for the diagnosis of Tuberculous 
meningitis in many studies. However there is no  unanimously accepted 
cut-off value to rule out tuberculosis affection of the  central nervous 
system. 
This study was undertaken to evaluate the role of adenosine 
deaminase in the diagnosis of tuberculous meningitis and to find out an 
appropriate cut-off value to achieve  acceptable sensitivity and  specificity 
levels 
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OBJECTIVES 
 
The study was conducted with the objective of 
 
(i) Evaluating the efficacy of CSF  adenosine deaminase activity in 
diagnosing tuberculous meningitis  
 
(ii) to find out a appropriate cut-off value for CSF ADA level for the 
diagnosis of tuberculous meningitis. 
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REVIEW OF LITERATURE 
HISTORY 
 Tuberculosis is one of the oldest human diseases.  Hippocrates (460-
373BC) called the disease pthisis, a Greek word which meant   to consume, 
to spit and to waste away1.  There has been references in the Vedas and it 
was called RAJAYAKSHMA. On 24th March, 1882, Robert Koch 
discovered the bacilli causing TB.  This day (March 24) is being observed 
worldwide as TB day2. 
INTRODUCTION 
 Tuberculosis is an infectious disease caused by Mycobacterium 
tuberculosis{MTB}.  This disease mainly spreads by droplet infection.  
Whenever a sputum positive patient coughs or sneezes, he throws millions 
of bacilli  in to the surrounding air.  When a healthy person inhales these 
bacilli, he gets TB infection. But in most conditions the development of TB 
in healthy individual is kept in a check by the immune system.  When the 
immunity is deranged, the person develops the disease.  TB affects all the 
organs except hair and nail.  One sputum positive patient can infect 10-15 
persons in one year and remain infectious for 2-3 years if left untreated. 
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 TB is called “CAPTAIN OF THE MEN OF DEATH”.  TB is the 
leading killer disease among the infectious diseases.  Among women, 
compared to the maternity related deaths, TB ranks higher3.   
 In India, per day 40,000 people are infected with TB bacilli and 
relatively 5000 people develop the disease.  One death every one and a half 
minute is being reported due to tuberculosis4. 
Microbiological aspects of MTB 
Mycobacteria are gram-positive rods. They measure 1 to 4 mm long 
and 0.3 to 0.6 mm in diameter; they are seen as clear rod-shaped zones in 
Gram’s stain.5  The high content of lipids in the cell wall of all MTB bacilli 
make them acid-fast. This is in the outer layer of the cell wall (glycolipids 
and esters of fatty acids). One of the water-soluble glycolipids is known as 
‘cord factor’. This has been related to the virulence of MTB. Mycolic acid  
though is specific for MTB, it is positive in many other organisms like 
Nocardia , Rhodococci , Cornyebacteria , Microsporidium , 
Cryptosporidium and few others6. Pathogenic MTB is fastidious with  
regards to culture conditions. The various methods of demonstrating MTB 
are: 
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• Ziehl-Neelsen  staining 
• Modified ZN staining 
• Auramine- Rhodamine staining7 
NEUROLOGICAL TUBERCULOSIS 
INTRODUCTION 
 Neurological tuberculosis comprises five to ten percent43 of the cases 
of extra-pulmonary TB.  With the emergence of TB as an increasingly 
common secondary infection in patients with HIV infection and AIDS 
there, is a resurgence of neurological TB cases.6  Even after the  invent of 
modern day antituberculosis treatment, neurological TB continues to have a 
high morbidity and mortality rate.   
CLASSIFICATION OF NEUROLOGICAL TUBERCULOSIS: 
• Tuberculous meningitis 
• Tuberculous arachnoiditis (TB radiculomyelitis) 
o Basal 
o Opticochiasmatic 
o Spinal 
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• Tuberculoma  
o Intracranial 
o Spinal 
•  Tuberculosis abscess 
TUBERCULOUS MENINGITIS 
 Tuberculous meningitis, the commonest form of neurological TB,   
accounting for about 70 to 80 percent of the neurological cases in 
developing countries, is a major health problem faced by the developing 
countries.  Inspite of its common occurrence, extensive research and wide 
spread awareness, there is often a delay in the diagnosis and institution of 
specific therapy for TBM. 
EPIDEMIOLOGY:56 
It is estimated that there are  3.3 million prevalent case of all forms of TB 
disease (smear positive Pulmonary tuberculosis, smear negative PTB and 
Extra-Pulmonary TB). The no. of TB suspects is gradually increasing over 
the last 10 years in INDIA. In India according to the 2010 data there  was 
an incidence of  1.98 million (168/lakh/year) cases of tuberculosis ( in all 
forms) and the prevalence was 2.18 million (185/lakh/year) . The 
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proportion of HIV positive patients in the Tuberculosis group was found to 
be 6.7% 
 However , this data refers to the tuberculosis in all forms for which 
Revised national tuberculosis control programme{RNTCP} was started. 
The data on extra-pulmonary TB is very minimal and there is hardly any 
data regarding the country wide incidence and prevalence of CNS 
tuberculosis. 
 
PATHOGENESIS8,13,15,16 
 Many of the symptoms, signs, and sequelae of tuberculous 
meningitis (TBM) are the result of an immunologically directed 
inflammatory reaction to the infection. TBM develops in 2 steps. 
Mycobacterium tuberculosis bacilli enter the host by droplet inhalation, the 
initial point of infection being the alveolar macrophages. Localized 
infection escalates within the lungs, with dissemination to the regional 
lymph nodes to produce the primary complex. During this stage, a short but 
significant bacteremia is present that can seed tubercle bacilli to other 
organs.  
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In persons who develop TBM, bacilli seed to the meninges or brain 
parenchyma, resulting in the formation of small subpial or subependymal 
foci of metastatic caseous lesions. These are termed Rich foci, after the 
original pathologic studies of Rich and McCordick.  Tuberculous 
pneumonia develops with heavier and more prolonged tuberculous 
bacteremia. Dissemination to the central nervous system (CNS) is more 
likely, particularly if miliary tuberculosis (TB) develops.  
The second step in the development of TBM is an increase in size of 
a Rich focus until it ruptures into the subarachnoid space. The location of 
the expanding tubercle (ie, Rich focus)10,11 determines the type of CNS 
involvement. Tubercles rupturing into the subarachnoid space cause 
meningitis. Those deeper in the brain or spinal cord parenchyma cause 
tuberculomas or abscesses. While an abscess or hematoma can rupture into 
the ventricle, a Rich focus does not.  
A thick gelatinous exudate infiltrates the cortical or meningeal blood 
vessels, producing inflammation, obstruction, or infarction. Basal 
meningitis accounts for the frequent dysfunction of cranial nerves (CNs) 
III, V,VI, and VII, eventually leading to obstructive hydrocephalus from 
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obstruction of basilar cisterns. Subsequent neurological pathology is 
produced by 3 general processes: adhesion formation, obliterative 
vasculitis, and encephalitis or myelitis.  
PATHOLOGY OF TBM13,14,15,16 
 The pathology of TBM comprises of  1)inflammatory meningeal 
exudates, 2)ependymitis 3)vasculitis, 4)disturbance of cerebrospinal fluid 
circulation and absorption. 
• Meningitis 
o Inflammatory leptomeningeal exudates 
o Caseous necrosis 
o Proliferative opticochiasmatic arachnoiditis  
• Vasculitis  
o Arteritis /  
o Phlebitis 
• Ependymitis and choroid plexitis 
o Cortical  
o Subependymal 
o Vasculitis and infarction 
• Hydrocephalus 
o Communicating 
o Obstructive 
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CLINICAL FEATURES 
 Prodromal phase is non specific and usually lasts for 2-3 weeks.  
This phase includes apathy, anorexia, vague ill-health, irritability and 
behavioural changes.  As a part of prodrome headache, vomiting and fever 
may occur and  heralds the onset of meningitis.  Focal neurological deficits 
and features of raised intracranial tension may precede the signs of 
meningeal irritation.  Focal and generalized convulsions are more common 
in children and elderly persons.  Cranial nerve palsies can occur.  Sixth 
nerve involvement being the most common13,14,15,16,55.Exudates around the 
optic chiasma is the central feature of the pathology.  Complete or partial 
loss of vision is the major complication of the disease. 
 In untreated cases, adhesions in the basal brain progress and result in 
extensive cranial nerve palsies.  Internal carotid occlusion and stroke, 
pupillary abnormalities, increasing hydrocephalus with tentorial herniation, 
pyramidal signs and progressive deterioration in the conscious state occur.  
In the terminal stage of illness, patient becomes comatose and result in 
decerebrate or decorticate posturing.  Without treatment, death usually 
occurs in 5-8 weeks. 
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 According to the severity of the illness, patient with TBM can be 
categorized into four clinical stages 
 
The prognosis of TBM is determined by the clinical stage at the time of 
initiation of treatment. 
TUBERCULOMA17,18,19,20,21 
 Tuberculoma is a mass of granulation tissue made up of a 
conglomeration of microscopic small tubercles.  It is due to 
hypersensitivity reaction to tubercular proteins in the susceptible 
individuals.  The size of cerebral tuberculomas is highly variable.  In most 
cases the diameter range from a few mm to 4 cm.  Intracranial 
STAGE DESCRIPTION10,42 
1 Conscious and rational, with or without neck stiffness, but no 
focal neurological signs or signs of hydrocephalus 
2 Conscious but confused or has focal signs, such as cranial nerve 
palsies or hemiparesis 
3 Comatose or delirious with or without dense neurological deficit 
4 Deeply comatose with decerebrate or decorticate posturing 
20 
 
tuberculomas in patients under the age of 20 years are usually infratentorial 
but supratentorial lesions predominate in adults.16,19  Solitary tuberculomas 
are more frequent than multiple lesions. 
DIAGNOSIS 
 Diagnosis of TBM is based on history neurological symptoms, signs 
and CSF findings.  Supportive features include radiological evidence from 
CT and MRI such as basal exudates, hydrocephalus, infarct, tuberculomas  
and gyral enhancement.   
DIFFERENTIAL DIAGNOSIS FOR TBM 
• Partially treated bacterial meningitis 
• Cryptococcal  meningitis 
• Viral meningo encephalitis 
• Carcinomatous meningitis 
• Neurosarcoidosis 
• Parameningeal infection  
• Neurosyphilis 
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INVESTIGATIONS 
• Chest X ray – reveals findings consistent with pulmonary TB in 
30-50 percent of adults.  
• Neuro imaging – CT/MRI22-26  
o May reveal thickening and enhancement of basal 
meninges, hydrocephalus, infarction, periventricular edema 
and mass lesions due to associated tuberculoma or TB 
abscess. 
o Common site of exudate are basal cisterna ambiens, 
suprasellar cistern and sylvian fissures 
o Hydrocephalus is the single most abnormality reported in 
more than 50 percent of the cases  
o Vasculitis and thrombosis associated with TB are seen on 
CT as multiple areas of hypodensity secondary to ischemic 
lesions. 
o Gadolinium  enhanced MRI is superior to CT in detection 
of basal meningeal enhancement and small tuberculomas. 
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• Tuberculin Skin Test{TST} 
o TST with purified protein derivative has been reported to 
be positive in 40-65 percent of cases. But this test lacks 
specificity. 
CSF FLUID STUDY :27 
CSF analysis forms a very important part in the diagnosis of TBM.  
CSF physical examination:  
The opening pressure of CSF may be high in some cases of TBM. 
The CSF can be clear , turbid or in some cases hemorrhagic.  If allowed to 
stand a pellicle or cobweb may form indicating the presence of fibrinogen.  
CSF glucose: 
The CSF glucose level is abnormal in majority of cases, being less 
than 40 percent of the corresponding blood glucose level.  Median glucose 
levels are reported to be between 18-45 mg/dl 
CSF protein: 
Protein content is 100-800 mg/dl.  In the presence of co-existing 
spinal meningitis and spinal block, the values can exceed 1000 mg/dl.   
23 
 
CSF cell count and cytology: 
In TBM, leukocyte count ranges between 100-500 cells/µlitre but 
rarely can exceed 1000 cells/µlitre.  Predominantly lymphocytes are 
increased but in acute stage  neutrophils  dominate the picture 
CSF for ZN staining : 
The detection rate of MTB in CSF by ZN staining ranges from 12.5 
– 69 %. The yield may marginally increase with auramine staining . The 
centrifuged CSF sample (30 min) and thick smear examination from the 
precipitate may enhance the detection rate of MTB. If there is a high index 
of suspicion, repeated samples should be sent for staining.  
CSF culture: 
The positivity of culture of CSF for MTB is 25-70% of cases using 
LJ media. However in many Indian reports, the yield has been poor up to 
19%. The yield can be increased by using liquid culture media such as 
septi-check AFB system and MGIT media. This may raise the sensitivity  
up to 80 percent of the cases. Culture remains the gold standard for 
diagnosis. The isolation rate of Mycobacterial tuberculosis is higher from 
cisternal and ventricular CSF than a lumbar puncture sample. 
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CSF ADA: 
It is elevated in CSF in 60 –100 % patients with TBM.  
CSF inferferon – : 
 It can be used to diagnose latent TB infection and the sensitivity may 
reach up to 80%.  
CULTURE METHODS:28-32 
It detects fewer bacilli. It is a definitive diagnosis. It helps to 
distinguish between Mycobacterial tuberculosis{MTB} and other 
mycobacterial organisms( atypical mycobacteria) . growth of MTB is 
extremely slow. The generation time is 18-24 hours. It requires special 
media  and this adds to the cost of diagnosis and treatment. Culture can 
detect as few as 10-100 bacilli /ml of sputum.  
Culture characters: 
Growth of MTB appears in 2 weeks but may be delayed up to 6 – 8 weeks. 
Optimal temperature required is 37 degrees.  
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IMAGE ATLAS: 
 
Figure 1: Growth of MTB on the LJ media. MTB grows as discrete dry 
wrinkled and irregular cream – buff coloured colonies.   
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Figure 2: The image on the left is the demonstration of AFB (MTB) using 
the ZN staining method and the image on the right is the demonstration on 
MTB using the Auramine – Rhodamine flouroscent staining method. 
 
Figure 3: MRI Image of a patient with TBM. Figure on the left is a T2 
sequence showing a right thalamic infarct (white arrow). Figure on the 
right is a post Gandolinium contrast T2 FLAIR sequence showing 
meningeal enhancement in the parietal , occipital lobe surfaces ( black 
arrow) and a tuberculoma ( seen a ring lesion)in the pontine region (black 
arrowhead) .This image demonstrates the multiple findings seen in TBM.  
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Figure 4: Neuro imaging in TBM. The image on the left shows the 
presence of dilated ventricles and cerebral oedema suggestive of 
hydrocephaleus and the image on the right shows the neuro-surgical 
intervention needed to relieve the hydrocephalus ( Ventriculo – peritoneal 
shunting ). 
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Culture Media : 
They can be divided into solid and liquid media. 
Solid Media: It is useful for isolation of organisms,  antigen preparation 
and chemical tests. Common examples are: 
Lowenstein Jensen Media ( most common ){contains 
Glycerol,egg,Asparagine,indicator Malachite green,certain mineral acids} , 
Loffler’s serum slope , Pawlowsky’s medium (potato medium), Tarshis 
medium (Blood medium ). 
Liquid Media : They are more useful for sensitivity testing. Common 
Examples are: Dubois media, Middlebrook’s medium, Sula’s and Sauton’s 
Media. 
Colony Characteristics: 
On solid media, MTB gives rise to discrete dry wrinkled and 
irregular colonies. Creamy white to begin with and then later become buff 
colour. In liquid media MTB grows as a wrinkled pedicle. A diffuse growth 
can be obtained by adding a wetting agent. Eg Tween 80. Serpentine cords 
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are generally formed by virulent strains while avirulent strains  grow in a 
disperse fashion. 
 Incubation is done at 37degrees and cultures are examined  initially 
after 3-4 weeks. This is done to rule out the growth of rapidly growing 
atypical  mycobacteria and fungi. A negative growth is said only after 8 
weeks of incubation.  
Rapid Culture methods: 
 In case of extra pulmonary specimen the time taken may be even 
longer. A technique for automated detection of bacterial metabolism is 
available. This measures radioactive carbon dioxide. This is generated from 
decarboxylation of carbon 14 labelled substrates. This principle is used in 
BACTEC culture methods. When the BACTEC 12B vial is inoculated with 
the specimen, the MTB in the specimen starts to grow using the palmitic 
acid ( radio C-14 labelled substance) and release radioactive CO2. The 
BACTEC instrument then measures quantitatively the radioactivity in 
terms of numbers on a scale ranging from 0 -999. This is designated as the 
growth index. The daily increase in the growth index is directly 
proportional to the rate and amount of growth in the medium. When an 
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inhibitory agent is introduced in the medium then metabolism gets 
inhibited. This is indicated by reduction in the growth index. 
Septi Check Acid Fast Bacilli Method is also a novel biphasic 
culture approach is available for the growth of MTB. 
Rapid liquid MTB culture methods 
 This is also known as MGIT( MTB Growth Indicator Tube). This 
culture is done using manual or automated systems. The tubes contain 
enriched Middlebrook’s 7H9 broth and oxygen sensitive fluroscent sensor. 
This is embedded in the silicon layer at the bottom of the tube.  An actively 
growing MTB consumes the dissolved oxygen and the sensor blooms and 
this indicates MTB growth. This can be observed with a 365nm UV lamp. 
MTB phage based Detection test: 
Phage based tests require   limited culture facilities and promise rapid 
results. Results can be obtained in about 2 days.  
IMMUNODIAGNOSIS: 
Antibody Detection Tests:33 
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The A60 antigen is the most extensively used antigen for both 
pulmonary and extra pulmonary TB in both adults and children. Ig G and 
IgM have been evaluated. The sensitivity is 30 – 100 %.  
Antigen detection tests: 
o Lipoarabinomannan urine test 
Nucleic Acid Amplification Tests: 
o Nucleic acid probes: 
This detects small amount of MTB with no cross  hybridization with non 
mycobacterial respiratory pathogens. It has a sensitivity equivalent to 
smear examination by ZN staining.  
Polymerase Chain Reaction35,36: 
  This is a very sensitive as well as specific method. A protocol 
for the detection of insertion element (IS6110) was described. It has a 
positive result in 60 % of MTB effusions. While a PCR for conserved 
region was positive in 20% of such patients. However, reports also say that 
when different specimens from the same patient were analysed 
intermittently positive results were obtained. 
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  Initially generations of PCR technique were able to detect as 
low as 10 bacilli in the specimen. Recent modifications have enabled the 
DNA extracted from a fraction of a bacilli to be found after suitable 
amplification. DNA ligase functions to link  two  stands of DNA together 
to continue a double strand segment. The seal can reliably take place only 
if the ends are complementary and there has to be exact match. In Ligase 
chain reaction the fragmented primers are 4 in number and are added in 
excess. Results are available in 3 days as compared to culture . It has been 
said the power of PCR is so high that its most important drawback is 
detection of a smallest amount of contaminated DNA of MTB and 
subsequently resulting in misdiagnosis. 
Genotype Assay:34 
 Two genotype assay are currently available , the first assay is for the 
diagnosis of MTB and the second is for the detection of MTB – drug 
resistance ( Rifampicin and Isoniazid ).  
Polymerase chain reaction sequencing: 
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Most protocols include the use of repeat insertion sequence IS6110 
as a target for amplification. This sequence is specific for MTB. This 
sequence is present in multiple copies in the genome of MTB. 
Identification of MTB by High Performance Liquid Chromatography: 
This rapid method is developed by the CDC ( centre for Disease 
Control, Atlanta) for the analysis of species specific MTB mycolic acids 
present in the cell wall of MTB bacilli.  
 
ADENOSINE DEAMINASE:57-85 
The conversion of adenosine to inosine is catalysed by the enzyme 
ADA.  It is a T-lymphocyte enzyme.  The plasma activity of ADA is rich in 
cellular immunity stimulated diseases.  The proliferation and differentiation 
of lymphocytes, mainly T-lymphocytes are  being influenced by ADA.  
ADA is released by the stimulation of live intracellular microorganisms.  
This is why, ADA is considered as cell mediated immunity marker, in 
particular for the activation of the T lymphocytes.   
Among the several isoforms of ADA, the most significant ones are 
ADA1 andADA2.   
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ADA1 has got equal affinity for both adenosine and 2’-
deoxyadenosine, where as ADA2 has got more affinity for adenosine. 
2’-deoxyadenosine/ADA1 activity ratio=0.75 
2’-deoxyadenosine/ADA2 activity ratio=0.25 
ADA1 is present in all cells whereas ADA2 is present only in monocytes 
and macrophages.  
False Positive ADA levels are seen in : 
• Neuro-brucellosis 
• Lymphoma 
• Few patients with Cryptococcal Meningitis 
• AIDS 
 
INTERFERON –  
INTERFERON-GAMMA RELEASE ASSAYS:{IGRA} 
 It is used to diagnose latent tuberculous bacterial infection.  
Interferon gamma is a cytokine, and a classic marker of  Th-1type cellular 
immune response.  It detects only some components of the cellular immune 
response .  for eg. IGRAs detect only one cytokine (interferon- ).  Several 
factors including host, microbial exposure and disease can impact the result 
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of this test.  Early versions of  IGRAs used PPD as the stimulating antigen.  
But newer versions use antigens that are more specific to mycobacterium 
tuberculosis than PPD.  These antigens include early secreted antigenic 
target 6 (ESAT6), culture filtrate protein 10 (CFP10).  These are encoded 
by genes located with in the region of difference 1 (RD1) segment of the 
MTB genome.  They are more specific than PPD.  This is due to non 
sharing property of it with any of the BCG vaccine strains or certain 
species of non tuberculous mycobacteria like mycobacterium avium. 
COMMERCIALLY AVAILABLE IGRAs:37-41 
• QuantiFERON-TB Gold{QTF-G} 
• T-SPOT.TB test 
The estimated sensitivity in patients with active TB is 75-95%. 
The estimated specificity in healthy individuals with no known TB disease 
or exposure is 90-100%. Using this test, results can be obtained in 1-2 days. 
LIMITATIONS OF IGRA: 
o High material cost 
o Requires well infrastructure laboratory 
o Requires highly trained personnel. 
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COMPLICATIONS OF TUBERCULOSIS MENINGITIS: 
• Raised intracranial pressure, 
cerebral edema, stupor 
• Basal meningitis with cranial 
nerve palsies 
• Focal neurological deficits 
• Hydrocephalus 
• Tuberculoma 
• Tuberculous abscess 
• Opticochiasmatic 
pachymeningitis resulting in 
visual loss 
• Tuberculosis arteritis and stroke 
• Endocrine disturbances 
• Hypothalamic disorder leading 
to loss of control of blood 
pressure and body temperature 
• Diabetes insipidus 
• SIADH 
• Internuclear ophthalmoplegia  
• Hemichorea 
• Spinal block 
• Spinal arachnoiditis 
 
TREATMENT:47,48 
Confirmation that a particular case is TBM seldom happens in each 
case scenario even after the employment of sensitive tests like culture , 
BACTEC ,PCR and ADA levels. This is especially a common scenario in 
developing countries like India. Sheller et al concluded that the most 
important principle in the successful management of CNS TB is the prompt 
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start of ATT on the basis of clinical suspicion even before the culture 
reports are awaited.  
Before starting the ATT it is of utmost importance to stage the 
disease and then decide on the treatment plan. The entire treatment of TBM 
can be divided into the following parts : 
• Role and duration of  ATT 
• Role of steroids 
• Surgical management 
ATT: (RNTCP guidelines):  
ATT under RNTCP for CNS tuberculosis is considered under a 
special category which includes Spinal TB as well. Patient should be 
referred to a tertiary care centre for evaluation as early as possible as the 
disease is fatal if left untreated. The total duration of treatment is 8 – 9 
months. The continuation phase should be given for 6 – 7 months . Steroids 
should be given initially and then gradually reduced over a period of 6 – 8 
weeks.  
Patient should be started on the following drugs: 
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o Isoniazid ( 10-15 mg/kg) 600 mg /d thrice weekly 
o Rifampicin (10 mg/kg) 450 mg /d ( if > 60 kg then 600 mg/d) 
thrice weekly 
o Pyrazinamide (30-35 mg/kg) 1500 mg/d thrice weekly 
o Streptomycin (15 mg/kg) 0.75 gm i.m.( if > 50 years then 0.5 
gm ) thrice weekly 
 In patients with TBM on category I{CAT-I} treatment  the four 
drugs used in the intensive phase should be HRZS instead of HRZE. The 
continuation phase consists of HR regimen. 
This recommended ATT protocol has been an extrapolation of the 
RNTCP guidelines for the management of pulmonary TB. This is because 
of the lack of randomized control trials to establish an optimal treatment 
course for CNS tuberculosis. There is an obvious difficulty in conducting 
such trials. This is due to the rarity of the disease , difficulty in confirming 
the diagnosis and a high mortality rate in advanced cases. Among the ATT 
drugs, it is found that both isoniazid and pyrazinamide pass very easily 
through the Blood brain barrier{BBB]49,50 and isoniazid remains the 
backbone of TBM treatment. Rifampin and ethambutol have comparatively 
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significantly less CNS BBB penetration . Yet they still play a significant 
role in the treatment of CNS tuberculosis.  
The emergence of Multi drug resistant tuberculosis{ MDR – TB}51 
has worsened the confusion on optimal treatment time to identification of 
the resistant bacilli is often prolonged and hence the time for appropriate 
ATT is often delayed by up to 2-3 months.It has been reported that the 
delay may even lead to the disease to progress to an advanced stage before 
the start of optimal ATT. There is no grading system that could predict 
MDR – TB. The MDR TB mortality is high and part of it can be definitely 
be attributed to the lack of adequate ATT when the disease was  first 
identified. 
MDR TB should be considered if  
• there is a positive history of prior Anti tuberculous therapy. 
• contact with a patient with MDR tuberculosis 
• poor clinical response to first-line TB therapy within 2 weeks 
despite a firm diagnosis and an adequate adherence to treatment.  
Much like the standard ATT , there is lack of  Randomised control trail for 
MDR TBM . Hence this adds to the further controversy on what should be 
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considered as a optimal ATT in MDR TB patients. The presence of 
inflamed meninges  help the CNS penetration of second-line agents such as 
aminoglycosides, Fluoroquinolones, even though are  able to penetrate the 
CNS, have been shown to have lower CSF levels than in the serum. 
Cycloserine and ethionamide  are other second-line agents that have good 
CNS penetration. They form a  strong basis of ATT for MDR TB. Though 
INH resistance is common in resistant TBM it has been proven to be 
effective and  hence is included in the TBM treatment regimen. DOTS 
PLUS [Cat-IV] Regimen is used to treat MDRTB patients under RNTCP 
programme. 
ROLE OF STEROID THERAPY : 
Since early 1950 , the role of steroid in treatment of TBM has been 
contemplated and till date it continues to be a controversial issue. The 
rationale behind the use of steroids is 44,45,46 : 
• reduction in the deleterious aspects of the immune response from the 
inflammatory mediators(proinflammatory cytokines and chemokines 
like TNF-α, IL-6, IL-1β, CCL2, CCL5, and CXCL10) to the MTB in 
the CNS 
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• ability to prevent the development of communicating hydrocephalus  
• prevention of vasculitis and related infarction 
• lowers CSF protein and globulin levels 
• achieves higher glucose levels sooner suggesting inhibition of 
bacterial growth and its metabolism. 
• Possible role in immune modification that influence the response of 
microglial cells 
Controversies in the use of steroid in CNS TB management: 
• steroids do not affect intracranial pressure  
• steroids do not reduce the extent of infarction  
• do  not reduce the basal lepto - meningeal enhancement 
• may not reduce the formation of tuberculoma 
 
Thwaites45,46,55 et al did a large placebo-controlled trial using 
dexamethasone as an adjunct to ATT for TBM in a population in Vietnam. 
They conclude a significant reduction in mortality in adults. Subgroup 
analyses revealed that the mortality benefit of steroids happened to all 
severity types of TBM and its complications. However this benefit was not 
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significant in patients who are coinfected with HIV. This study was a 
landmark trial and did resolve some of the controversies in the favour of 
use of steroids as an adjunct to ATT in the treatment of TBM. 
Centers for Disease Control(CDC), and American Thoracic 
Society(ATS) hence in their  guidelines endorse the use of steroids in TBM 
treatment. Recommended dosing regimen is dexamethasone , to be initially 
started at a dose of 8 mg/day for pediatric patients weighing less than 25 kg 
and 12 mg/day for pediatric population children weighing above 25 kg. A 
dose of 12 mg / day was advised for the adult patients of TBM. This should 
be continued for for 3 weeks and then dose reduction should begin 
gradually during the next 3 weeks. The recommended oral steroid regimen 
for the treatment of TBM is predisolone 0.75 – 1 mg/kg/day in adults and 
0.25 – 1 mg/kg/day in children.      
POSSIBLE INDICATIONS FOR CORTICO STEROIDS IN 
TUBERCULOUS MENINGITIS: 
• Clinical 
o Clinical stages 2 and above 
o Evidence of raised intracranial pressure 
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o Focal neurological deficits suggesting arteritis 
• Radiological 
o Cerebral or perilesional edema 
o Hydrocephalus 
o Infarcts 
o Opticochiasmatic pachymeningitis 
ROLE OF SURGERY 54: 
The role of surgery in the management of TBM is revolves around 
the dealing of serious complications like hydrocephalus, reduction of the 
mass effect of developing tuberculomas and drainage of MTB brain 
abscesses. The development of hydrocephalus is thought to be due to  
• basal meningitis that  blocks the exit of CSF from its 
absorption in the arachnoid villi  
• possible destruction of the arachnoid villi. 
Hydrocephalus can be managed by serial lumbar punctures and surgically 
by  external ventricular drainage, or ventriculoperitoneal shunting 
procedures. Communicating hydrocephalus usually requires surgical 
drainage but there is a definite role for the use of steroids and diuretics 
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while non-communicating hydrocephalus needs surgical drainage in almost 
all cases. There is a controversy in the timing of surgery especially in the 
pediatric age group given a success rate of about 40 % and a complication 
rate of 30 %. The outcome of patients co-infected with HIV is poorer as 
compared to non HIV infected patients with hydrocephalus. Recent 
advances include the role of neuro-endoscopy in relieving hydrocephalus 
which may reduce the dependence on shunt procedures.  
The use of ATT and steroids had almost reduced the need of surgery 
for tuberculomas and it is now reserved for only those cases with tendency 
to cause a mass effect. MTB brain abscess requires drainage, either an 
aspiration via a burr hole fractional drainage, or repeated aspiration through 
a stereotactic approach or in some cases total excision of the abscess. 
PROGNOSIS:  
Clinical symptoms may improve quite slowly.  Transient worsening  
may happen despite appropriate ATT. New tuberculomas may develop.  
Such developments do not require the change in the treatment strategy in 
almost all cases. The possible exception could be the need to  prolong the 
use of steroids which may mitigate the complications developing.  
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The mortality rate of treated TBM ranges from 20 to 50% . A large 
case series from Egypt about  1430 TBM patients. They found a mortality 
rate was 57%. A major prognostic marker for mortality is the stage of 
disease at which the ATT was started. It ranged from 18% for stage 1 to up 
to 70 % for stage 3 disease. 
Other prognostic markers of poor prognosis  are : 
• the duration of 
symptoms (4 weeks 
symptomatology period 
had a 40 % mortality) 
• use of steroid  
• children with an 
advanced stage are 
having a poor prognosis 
than adults.  
• presence of any 
vasculitic infarct  
• HIV coinfection  
• isoniazid and rifampin 
resistance  
• high CSF lactate 
• CSF leucopenia 
• low CSF glucose 
 
A study done by Mishra et al53. concluded that features such as 
presenting high  intracranial pressure, cytokines in the CSF, streptomycin 
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resistance and MTB have been shown not to be significant predictor of a 
poor outcome.  
SEQUELAE OF TUBERCULOUS MENINGITIS : 
Among the survivors of TBM, some form of neurological 
impairment afflicts approximately 20 to 30%. They include : 
o Psychological or 
psychiatric disturbances 
o Visual defects 
o Focal neurological 
deficit 
o Endocrine disturbances 
o Seizures 
o Intracranial calcifications 
o Hearing defects(often 
drug induced) 
TUBERCULOUS MENINGITIS AND HIV INFECTION52 
HIV infection is now considered as the single most important risk 
factor for the activation of latent tuberculosis. And it has become almost 
routine to look out for HIV – TB co infection in patients diagnosed as HIV 
infected or Tuberculosis first. 
HIV infection increases the prevalence of neurological tuberculosis also 
as it increases the prevalence of pulmonary TB. The profound immuno 
compromised state in HIV infection is probably responsible for the 
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significant change in the clinical presentation, radiologic manifestation and 
histopathology of the affected organs.  
In the case of neurological tuberculosis there is more cognitive deficit if 
the patient is HIV co-infected. The Neuro-radiological imaging in such 
patients shows a lesser incidence of meningeal enhancement and 
communicating hydrocephalus. There is remarkable less amount of 
gramulamatous exudates in the basal cistern regions. However 
periventricular white matter infarcts are more common. Tuberculoma like 
lesion seen in HIV patients usually turn out to be cerebral toxoplasmosis. 
There is co-existence of multiple infection affecting the CNS in HIV 
infection. 
There is a controversy if the HIV infection predisposes to the higher rate 
of treatment failure and  resistant bacilli incidence. Controversy also exists 
on the management of HIV – TB coinfection . This is due to reduced 
adherence to polypharmacy, prolonged treatment duration, overlapping 
side-effects, and the development of IRIS. 
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LUMBAR PUCTURE: 
A commonly done bedside procedure to collect cerebrospinal fluid 
(CSF). It is a useful diagnostic tool in diagnosis of central nervous system 
infective and inflammatory diseases. A therapeutic lumbar puncture can be 
done to relieve increased intracranial pressure and for administration of 
anaesthesia and intrathecal chemotherapy. 
INDICATIONS: 
1. Central nervous system infections: meningitis, encephalitis, myelitis 
2. Inflammatory diseases: multiple sclerosis, Guillian barre syndrome 
3. Carcinomatous meningitis 
4. Subarachnoid hemorrhage 
5. Spinal and epidural anaesthesia 
6. Intrathecal chemotherapy 
CONTRAINDICATIONS: 
1. Cardiorespiratory 
compromise 
2. Cerebral herniation 
3. Bleeding diathesis 
4. Local sepsis 
5. Previous lumbar surgery 
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PROCEDURE: 
The lumbar puncture technique and the risks involved should be explained 
to the patient and an informed consent should be obtained. A fundoscopic 
examination should be done prior to the procedure. Computed tomography 
of the brain should be done if needed.  
             The patient should be in a lateral decubitis in a fetal position with 
full flexion of neck and full flexion of knees upto chest. This posture 
widens the gap between the spinous processes. Another alternative position 
would be to have the patient sitting in a stool with head and shoulders bent 
forward. The needle should be inserted in the midline at the level of a line 
joining the superior aspects of the two iliac crests in the space between 
L3/L4 or L4/L5 vertebrae. Palpate the bony landmarks. 
Mark the site of insertion. Paint the area with topical disinfectant in 
concentric circles. A local anaesthetic is injected subcutaneously. Insert the 
spinal needle at the marked site with the stylet in place at the superior 
border of inferior spinous process directed towards the umbilicus. 
              The spinal needle will pass through the following layers: skin and 
subcutaneous tissue, supraspinous ligament, interspinous ligament, 
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ligamentum flavum, posterior epidural space, dura into the subarachnoid 
space and in between the nerve roots of cauda equina. When the 
ligamentum flavum is reached a popping sensation is obtained. Insert the 
needle in 2mm increments and withdraw the stylet to look for CSF. If there 
is no flow, withdraw the needle upto the subcutaneous plane and redirect 
the needle. If there is poor flow, rotate the needle by 90 degrees and check 
for CSF. If there is traumatic bleeding, the initial CSF is blood stained but 
with collection of additional fluid the blood tinge clears. The smallest 
volume of fluid required should be collected, usually around 10 ml. 
Replace the stylet and withdraw the needle. Dispose it in appropriate 
containers. The patient should be monitored for any complications for 
atleast 24 hours. 
COMPLICATIONS: 
1. Cerebral herniation 
2. Pain- local or referred 
3. Bleeding 
4. Infection 
5. Subarachnoid epidermal cyst 
6. CSF leakage 
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METHODOLOGY: 
Source of Data: 
A total of 55 patients attending the department of Internal Medicine 
of Government Stanley Medical College, Chennai  and Government 
Hospital of Thoracic Medicine, Tambaram under Government Stanley 
Hospital on  in-patient basis were included in this study. 
Duration of Study :  
 6 months[ April 2011 to September 2011] 
Inclusion criteria: 
Patients with features of  subacute / chronic Central nervous system 
infection   
 
Exclusion criteria:  
1. Paediatric population. 
2. Proven non-mycobacterial meningitis 
3. Proven carcinomatus meningitis 
Methodology: 
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All patients with features of sub acute/ chronic meningitis and with 
clinical features suggestive of Central nervous system infection were 
admitted in the internal medicine department  wards. After getting an 
informed consent from the patients, they were included in this study. 
The following data were noted: 
1. Age, sex 
2. Clinical features – fever duration , cough duration , weight loss, seizure, 
headache, neck pains, neck stiffness, vomiting , limb weakness and other 
features suggestive of  focal neurological deficit. 
3. Previous history of tuberculosis, contact with tuberculosis, 
4. Co morbid illness: HIV and Diabetes mellitus 
5. Personal Habits : smoking , alcoholism 
Then the patient was clinically examined and the following data was 
collected. 
  
The following investigations were done: 
1. Complete Haemogram 
2.  ESR 
3. Mantoux test 
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4. Chest X ray PA view 
5. Sputum Analysis ( AFB staining) 
6. HIV ELISA test 
7. In some cases , according to the affordibiltiy of the patient, neuro-
imaging was done. These included CT scan ( plain or with contrast 
)of the Brain and MRI imaging ( with or without contrast )of the 
Brain. 
8. A CSF analysis was planned. 
 
In all our patients included in this study , a written informed consent was 
taken and then according to the above mentioned standard method with 
aseptic precautions , a lumbar puncture was done. About 10 ml of CSF was 
collected ( including 5 ml for LJ media culture inoculation)   
The following things were analysed in the collected CSF samples: 
1. CSF sugar , protein 
2. CSF cytology and cell count 
3. CSF Gram’s staining 
4. CSF AFB staining 
5. CSF culture in Aerobic and Anerobic Media 
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6. CSF culture in LJ media 
7. CSF ADA levels 
The CSF - ADA level was calculated by using the Colorimetric method. 
 
The 5 ml CSF sample collected in a sterile test-tube was sent in a 
cold box immediately to TAMBHARAM SANATORIUM for culture 
using the  Lowenstien-Jensen medium. The inoculated culture media was 
followed at 4 weeks and 8 weeks intervals. If there is no growth  even  after 
8 weeks, the culture was considered to be negative. Treatment  with ATT 
and steroids was primarily started on the basis of high CSF protein levels 
,low CSF glucose levels and characteristic neuroradiological imaging ( if 
present ). In all patients before starting ATT counseling about the treatment 
, its duration and side-effects was given.  A basal liver function test was 
done. Then patients were started on ATT under national RNTCP 
programme( tab. Isoniazid 600mg/d ; tab.Rifampicin 450-600 mg/d ; tab 
Pyrazinamide 1500 mg/d ; tab Ethambutol 1200 mg/d anf Inj. Streptomycin 
0.75 gm/i.m/d given on 3 days every week ) during the hospital in - patient 
stay they were started treatment with inj. dexamethasone 8 mg tds i.v. for 1 
week , followed by 8 mg iv bd for 1 week followed by 8 mg i.v. od for 1 
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week and later it was converted to oral prednisolone 1mg/kg/day od for 2 
weeks and then tapered to 0.5 mg /kg/day for the next 3 weeks. Repeat LFT 
was taken at the end of 2 weeks of ATT to ensure no hepatotoxicity. 
Patients who showed symptomatic improvement at the end of 15 days and  
continued to be asymptomatic on the follow up of 2 months were 
considered to be showing a good response to ATT. 
 The following present in X-Ray Chest PA view were considered to 
be marker of TB infection : 
- Cavity ( thin walled , thick walled ) B/L extensive parenchymal 
infiltration , miliary shadows )  
The following features if present in MRI imaging were considered to 
be a marker of CNS TB infection: 
-  Basal meningeal exudates , hydrocephalus and Tuberculomas  
The patients were divided into two groups: 
1. TBM group ( based on positive C/S reports , typical  neuro-
radiological imaging features or a good response to given ATT )  
2. Non TBM group ( based on positive gram’s staining , positive India 
Ink staining , absence of typical neuro-radiological findings , poor 
response to the ATT )  
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The efficacy of CSF-  ADA level in the diagnosis of tuberculosis and in 
differentiating from non tuberculous causes of meningitis was evaluated. 
The data collected was submitted for statistical analysis. The significance 
was calculated using the Chi-square test and independent variable T test. 
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RESULTS: 
Age Distribution : 
Table-1 : Age distribution of  the entire study population 
In both the groups the age group (31-40) had maximum no. of patients. 
Gender Disribution : 
Table-2 :Gender Distribution 
Sex No.  Percentage No( TBM 
group) 
Percentage 
Male 31 56.40 23 53.50 
Female 24 43.60 20 46.50 
Total 55 100 43 100 
Age Group ( 
Yrs) 
No of  
Patients Percentage 
No of  
Patients in 
TBM group 
Percentage in 
TBM group 
< 20 Yrs 4 7.30 4   7.30 
21 – 30 13 23.60 11 25.60 
31 – 40 22 40.00 19 44.20 
41 – 50 12 21.80  8 18.60 
51 – 60 4 7.30 1   2.30 
Total 55 100 43 100 
Mean ± Sd 35.18 ± 9.97 33.37 ± 9.13 
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 According to this table there is a higher prevalence of TBM in male 
individuals. 
FEVER DURATION: ( TBM group ) 
Table-4: Fever duration ( in days)   
Sex Mean Sd Min Max t-value P-value 
Mean 19.26 3.66 13 30 1.67 
 
 
 
0.102 Female 21.30 4.33 
Total 20.21 4.07 
   
According to this table, in our study the average duration of fever 
was about 20 days  in the TBM group. And there was no statistical 
difference in the duration of fever according to sex. 
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SYMPTOM ANALYSIS( TBM group): 
Table 5 : symptoms in the TBM group  
Variable Male( N=23 ) Female(N=20) Total(N=43 
) 
No. %     
LOW 17 39.53 17 39.53 34 79.06 
Head ache 23 53.48 19 44.18 42 97.67 
Neck Pain 6 13.95 7 16.27 13 30.23 
Vomiting 16 37.20 10 23.25 26 60.46 
Meningeal Signs 12 27.90 8 18.60 20 46.51 
FND 4 9.30 6 13.95 10 23.25 
Seizures 5 11.62 8 18.60 13 30.23 
Positive TB Contact 4 9.30 7 16.27 42 25.58 
Positive Chest X-Ray 11 25.58 9 20.93 13 46.51 
Montoux 11 25.85 7 16.27 18 41.86 
HIV Co-infection 5 11.62 1 2.32 6 13.95 
 
 According to this table, Loss of weight was complained by about 
79% patients while headache , neck pain and vomiting was complained by 
98% , 30 % and 60 % respectively. 14% patients had HIV – TB 
coinfection. Chest radiography showed positive findings in  47%. 30 % had 
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seizures and 23% had a focal neurological Deficit. Meningeal signs were 
present in 47%. 
 
Table 5: CSF ANALYSIS  
CSF 
ANALYSIS 
Male  Male (%) Female Female(%) total Total 
% 
Clear 
  Turbid 
13 
10 
56.50 
43.50 
10 
10 
50.00 
50.00 
23 
20 
53.50 
46.50 
COBWEB 3 - 0 - 3 6.97 
Grams 0 0 0 0 0 0 
Positive 
growth of  
MTB in LJ 
media. 
16 37.20 13 30.23 29 67.44 
 Male mean Female 
Mean 
Total 
Mean 
Min Max t- 
value 
Sugar 35.57±5.47 31.70±3.90 33.77  24 46 2.63 
Protein 59.61±7.96 57.35±4.65 58.56  46 86 1.11 
Lymphocytes 
in CSF 
10.60±3.83 10.55±4.16 10.60    0.084 
ADA 15.66±3.61 15.03±3.24 15.36 7.40 23.40 0.600 
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 According to this table, the CSF in the TBM group was more often 
clear (54%) than turbid (46%). Cobweb formation was seen in only 3 
patients (7%). There was a positive MTB growth in LJ media in only up to 
67% of patients. The biochemical parameters of the CSF in the TBM group 
were Sugar -33 mg % , Protein 60mg % with a lymphocyte predominant 
CSF cytology and a mean lymphocyte count of 11 cells/mm. The mean 
ADA level was 15.66 ± 3.61 for males, 15.03 ± 3.24 for females. 
 
Table-8:  Haemogram parameters in the TBM group 
 
 Male Female Total Min Ma
x 
t-
value 
P-
value 
Hb 13.34±1.39 11.06±1.14 12.28±1.71 10 15 5.83 0.000 
TC 6102.17±122
0.2 
6612.50±138
5.6 
6339.53±130
9.5 
440
0 
9800 1.28 0.206 
P 39.48±4.51 39.25±4.59 39.37 ±4.49 29 50 0.16 0.870 
L 57.52±3.86 56.90±3.63 57.23±3.72 50 64 0.54 0.591 
M 1.70±1.40 2.00±1.38 1.84 ± 1.38 0 4 0.51 0.478 
ESR 43.83±8..51 39.20±4.46 41.67 ± 1.38 33 64 2.18 0.035 
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 According to this table, the mean TC was 6340 and a mean DC was 
(P-39 , L-57, M-2). Mean ESR was 39.2 mm /hr.   
ADA and its Cut – off value for TBM 
 
Table: ADA at different cut-off values: 
ADA cut 
– off 
Sensitivity 
% 
Specificity 
% 
PPV 
% 
NPV 
% 
P value 
10.5 90.7 50 86.67 60 0.0042 
11 90.7 50 86.67 60 0.0042 
12 90.7 83.33 95.12 71.43 0.0001 
12.5 86.05 83.33 94.87 62.50 0.0001 
13 79.07 83.33 94.44 52.63 0.0001 
13.5 72.09 83.33 93.94 45.45 0.0008 
14 65.12 91.67 96.55 42.31 0.0007 
14.5 60.47 100 100 41.38 0.0001 
 
 According to this table , as the CSF ADA activity level increases 
there is an increase in the specificity. The sensitivity drops if a higher cut-
off is chosen. If a cut-off of 14.5 IU/L is chosen the specificity and positive 
predictive value reaches 100% but the sensitivity falls to 60%. A Cut-off of 
12 IU/L gives a sensitivity , specificity , positive predicitive value and a 
negative predictive value of 90.7, 83.33 , 95.12 and 71.43 respectively.  
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The causes of Non TBM group 
Table: Non TBM group 
Possible Etiology Number ( percentage ) Tests used to confirm 
and other remarkable 
findings. 
Bacterial Meningitis 
other than MTB 
6  ( 50% ) Gram’s Stain. Strep 
pneumonia was isolated 
in 4 of the samples. 
Cryptococcal 
Meningitis 
2 ( 16.67% ) Confirmed with India 
Ink Staining , both cases 
were HIV positive.   
Carcinomatous 
meningitis 
2 (16.67% )  1 case had Gastric 
Adenocarcinoma 
1 case had a CML based 
bone marrow aspiration 
study 
Unknown  2 ( 16.67% )  
 
 According to this table the most common etiology in the Non TBM 
group was bacterial meningitis which was probably partially treated(50%). 
There were 2 patients with cryptococcal meningitis and carcinomatous 
meningitis each (16.67 % each ). There were 2 patients where we were 
unable to fix a final diagnosis with the available set of facitlites.  
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Table :Comparison between the Groups 
 HIV Positive 
patients 
Non TBM 
group 
TBM group 
No. of patients (%) 9 ( 16.36% ) 12 43 
Age (mean )in years 42.11 41.67 33.37 
Sex ratio ( M : F) 5:3 2:1 1.15 : 1 
Mean Fever 
duration(days) 
19.77 20.33 20.21 
LOW/ LOA (%) 66.67 16.67 79.06 
Headache(%) 100 100 97.67 
Neck pains(%) 44 66.67 30.23 
Vomiting(%) 56 83.33 60.47 
Meningeal Signs(%) 66 75 46.51 
FND(%) 22 25 23.25 
Cough with 
expectoration(%) 
56 % 25 % ( 
average 
duration of 
cough 19 
days) 
39.53% 
(average 
duration of 
cough 18.11 
days) 
Seizures(%) 44 25 30.23 
HIV infection(%) --- 3 of 12 ( 25 % 
) 
6 out of 43 
(13%) 
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HIV Positive Non TBM group TBM group 
TB contact(%) 11 None 25.58 
Sputum AFB(%) 0 None  
X- chest Lesion of TB(%) 11  8 46 
Response to ATT(%) 67 None 100 
Mean Hb (gm %) 13.35 12.7 12.28 
Mean Total Count ( P , 
L , M ) 
6637 ( 47.22, 
49.22, 2.11) 
8505 
(53.91,41.66,1.75) 
6339 (39.37, 
57.23,1.84 ) 
ESR mean 43.22 mm /hr 42.33 41.67 
Positive Montoux test 
(%) 
11 None 41.86 
CSF (clear : turbid) 5:4 3:9 23:20 
CSF sugar 33.55 31.58 33.77 
CSF protein 59.55 64.08 58.56 
CSF Lymphocytes 11.33 8.16 10.60 
Mean CSF ADA levels 13.36 ( TBM 
group and HIV 
positive  – 15.4 
; non TBM 
group and HIV 
positive  -9.16) 
9.56 23.40 
Positive Culture for 
TBM in LJ media   
( 4 out of 5 ) 
66.67 % in 
HIV and 
TBM group 
Nil 67.44 % 
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According to this table the non TBM group patients had a mean age 
around 42 years with a male preponderance. All had headache as their 
presenting complaint , 17 % complained of weight loss. 25% patients had 
either seizure or focal neurological deficit or were having a HIV positive 
status.   
 
According to this table , the yield of CSF for MTB in patients with 
TBM and HIV co-infection is the same as the patients with Non HIV 
positive – TBM. The calculated sensitivity,specificity,positive predictive 
valve and negative predictive valve for this table at ADA >12iu/l is 
93.1%,80%,93.1%,80% respectively. 
 
 Culture Positive 
TBM 
Proven Non 
TBM  
Total 
CSF ADA > 12 27 2 29 
CSF ADA < 12 2 8 10 
 29 10 39 
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DISCUSSION 
 In our study , from a total of 55 patients ,we included a total of 43 
patients in TBM group and 12 patients in the non TBM group. The yield of 
CSF culture in LJ media is low and considering only culture positive 
patients in the TBM group would include significant no. of true negatives 
into the non TBM group. This may lead to a large defect in the 
interpretation of results. Hence patients were considered to be suffering 
from TBM based on the results of CSF culture for MTB and positive 
neuro-radiological imaging findings and a good response to ATT. This is 
also supported by the following studies where there was a division among 
patients as TBM and non TBM based on findings other than positive 
culture alone.  
There has always been a controversy on the cut-off value of ADA in 
the CSF to consider it to be positive and suggestive. The following has 
been the analysis of similar studies in the past. 
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According to Gupta57 BK et. Al, when a study on 19 tubercular 
patients, 18 had CSF ADA above the cutoff value. Among 21 patients with 
non-TB patients, 2 had ADA levels above the cutoff value They concluded 
that ADA level estimation in CSF with 10 U/L as a cutoff value had 
94.73% sensitivity ,90.47% specificity, 90.00% positive predictive value. 
They suggest ADA should be given a place in routine evaluation of chronic 
meningitis  
According to Karsen et al58. a cut-off value of 12.5 IU/L had a 
sensitivity of 92% and specificity of 98% in differentiating TBM from non 
–TBM cases.They also found that if a cut-off of 6.45 IU/L is used then the 
sensitivity becomes 100% but specificity remains 92%. They suggested to 
use cut-off of 11 IU/L (sensitivity 92% and specificity  90%) and 
concluded in favour of cost-effectiveness of use of ADA. 
According to Xu et al59 , a study of 10 patients when undertaken. 
Sensitivity – 79% , specificity 91%, positive likelihood ratio 6.85 , negative 
likelihood ratio 0.29 and diagnostic odds ratio 26.93, was obtained with a 
cut-off of 12 IU/L.  
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According to Moghtaderi A et al60., when a study on 42 patients was 
done the TBM had an median ADA of 22 and in the  non-TBM group it 
was 8.0. They suggested the cut-off value of 10.5IU/L and achieved a 
sensitivity and specificity of 81% and 86% respectively. 
Pinheiro FV, et al61 did a study  to investigate CSF- ADA as 
additional marker of HIV infection in 26 patients with HIV. ADA activity 
correlated well with a sensitivity of 50% and specificity of 82.76%. 
According to Rana SV et al62., a study when done to compare ADA 
activity TB-PCR in CSF as a marker of TBM on 54 patients with suspected 
TBM found that a cut off of 10U/L, gave a sensitivity of 92.5% and 
specificity of 97% . They also suggested that ADA is a more sensitive 
indicator of TBM than TB-PCR in CSF. 
Feres MC et al63., compared the pleural fluid and CSF ADA activity 
in suspected TB patients. 94 pleural fluid and 40 CSF samples were 
studied.0.96 and 0.95 were the correlation coefficients for Pleural fluid and 
CSF samples. They suggested a cut-off of 9 IU/L and also validate the 
automated method for ADA estimation in samples. 
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According to Gautam N64 and others, CSF- ADA in TBM was 
calculated in 20 (TBM ) and 25 (non – TBM ) patients. The sensitivity was 
85%  and specificity was 88.0% at cut-off value of 6.97 IU/L. They 
conclude that ADA activity should be considered as a better and reliable 
approach especially in developing countries. 
According to Kashyap RS et al65., studied CSF - ADA activity in 153 
patients; 27 TBM patients, 39 clinically suspected TBM and 87 non-TBM 
patients. They concluded that ADA has a sensitivity of 83% and specificity 
of  86%. They also suggested that performing ADA (by any method ) is 
useful in low income countries. 
Chotmongkol V et al66,studied CSF – ADA in 16 cases of TBM, 53 
cases on non – TBM and 108 controls. They found that the mean in TBM 
group was 39.44 which was significantly higher than both the other groups. 
They suggested a cut-off of 15.5 U/I . This gave them sensitivity - 75% and 
specificity - 93%. They also supported the use of CSF ADA activity as a 
useful tool in the rapid diagnosis of TBM. 
Kainthla RP et al67., also found a significantly higher  CSF – ADA 
activity in TBM than in non TBM patients. The mean was 14.31 in TBM 
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group,  9.25 in non-TBM group and 2.71 in control population. According 
to them a 11.39 IU/L can be taken as cut-off value. This gave sensitivity of 
82% and specificity of 83%. They validated its use in countries with less 
sophisticated facilities. 
Jakka S et a68l tried to evaluate the role of ADA in predicting the 
adverse outcome in TBM.  After eliminating confounding factors like age, 
gender, CSF parameters, including cell count, lymphocyte and glucose, 
protein, and LDH levels between the two groups of patients. Patients with 
adverse outcome had  CSF-ADA level  17.1IU/l  which was significantly 
higher than patients with no adverse outcome (11.3 IU/L). They concluded 
that higher ADA activity may be associated with adverse neurological 
outcome in patients with TBM. 
Corral I et al69., ADA activity was studied in 417 CSF samples of 
HIV positive patients with neurological symptoms. They found that ADA 
levels were not significantly elevated in HIV-associated neurological 
disorder and progressive multifocal leukoencephalopathy. They suggested 
a cut-off of 8.5 IU/l for the diagnosis of TBM and this had 57% sensitivity 
and 87% specificity. But they also noted that false-positive results could be 
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obtained from CMV, candidial , cryptococcal, lymphomatous meningitis. 
Hence they conclude that the TBM diagnostic utility of ADA is limited in 
HIV positive patients. 
Correa MF70 studied ADA activity in Spanish population. They 
suggested a cut-off of 8.0 U/L. This gave a sensitivity of 81% and 
specificity of 91%. The TB - PCR sensitivity was 80 % and specificity of 
97 %. They too validate use of CSF- ADA activity for TBM diagnosis. 
Choi SH et al71., studied CSF – ADA  in 182 patients with 
meningitis. This study included 36 patients with TBM ,130 cases of aseptic 
meningitis,9 cases of bacterial meningitis and 7 cases of fungal meningitis. 
The mean ADA in the TBM group was 12.76. This was significantly higher 
than that in the rest of the groups. The sensitivity of 83% and specificity of 
95% was calculated using a cut-off value of 7 U/l was used. Values >15 U/l 
were not seen in any of the non-TBM patients. Hence they conclude that  
ADA activity >15 U/l can be used as a strong indicator TBM. They 
conclude that CSF ADA activity can be used to diagnose TBM early from 
other causes of chronic CNS infection with good reliability. 
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Schutte CM et al72. analysed the role of ADA isoenzymes with an 
intention to note the ratio of ADA-2 : total ADA in TBM (15 patients) and 
non-TBM group(11 patients).  The ratio of ADA-2 : Total ADA  > 0.8 in 
almost all patientsTBM.This ratio was significantly different in the non-
TBM group and hence this reflected the monocyte-macrophage origin of 
the ADA-2. 
Gambhir IS et al73. studied 60 by dividing them into TBM and non 
TBM group of 24 and 36 patients respectively. Non-TBM group included 
pyogenic meningitis ,viral encephalitis, aseptic meningitis, cerebral malaria 
and enteric encephalopathy.CSF- ADA activity was 9.61 and was 
significantly elevated as compared to non-TBM group. They suggested use 
of 8 IU/L as cut off value for diagnosis of TBM .They gave a sensitivity of 
44% and specificity of 75% at this level. 
According to Mishra OP et al74. who studied 27 pateints with TBM 
,29 non TBM patients and 10 control subjects. CSF ADA activity level was 
significantly high  (p < 0.001) in TBM patients. They suggested a cut –off 
of 5 IU/L It had a sensitivity and specificity of 89 and 92 %. They also 
concluded that the levels did not differ significantly with different stages of 
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TBM. They also found that there is significant correlation between CSF – 
ADA and CSF lymphocyte count, protein concentration and lymphocyte : 
neutrophil ratio.  
Rohani MY et al75. also studied the value of CSF – ADA in 
Malaysian population. They suggest a cut of 9 IU/L after studying 14 
patients with TBM. They gave a specificity of 87.6% at this level. They 
suggested that CSF-ADA level should be interpreted as a rapid marker for 
tuberculosis along with clinical correlation. 
Machado LD et al76. studied CSF - ADA activity in 263 patients with 
AIDS. They found that an elevated CSF - ADA activity can be present in  
CSF  with toxoplasmosis, neuro-syphilis, neuro - CMV , cryptococcal 
meningitis and lymphomatous meningitis. Hence they concluded that the 
utility of CSF –ADA activity is limited in HIV positive patients with 
neurological manifestations as compared to patients who are not infected 
by HIV. 
According to Mishra OP et al77. CSF-ADA activity measurement and 
levels of C-reactive protein when done in 27 patients with TBM and 8 
patients with non-TBM showed significant alterations. A cut-off ADA 
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level of 5  IU/L and CRP positivity was suggested to be used as a tool to 
differentiate TBM from non TBM patients. Their study had a 75 % and 100 
% sensitivity and specificity. Since both the tests are simple and generate 
rapid results, they stress the importance of this test to differentiate TBM 
from non-TBM causes of meningitis. 
López-Cortés LF78 ,Egido JA79 ,Abduljabbar MS80 pointed out that 
CSF – ADA may give false positive results with neuro brucellosis and that 
the efficacy of CSF –ADA is reduced in HIV positive individuals. 
 Yu SZ et al81, Baki A et al82 , Coovadia YM et al83  assert the use of 
CSF – ADA in TBM diagnosis in their studies. 
 Donald PR et al84 studied 27 TBM patients, 40 with aseptic 
meningitis, 31 with bacterial meningitis. Both the CSF: serum ADA ratio 
and the absolute CSF ADA levels  were higher in TBM . They conclude 
that both values can distinguish TBM from non TBM but they suggest 
correlation with the other CSF markers of TBM like Glucose , protein and 
lymphocyte count. 
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Blake J et al85. conclude that TB effusion have higher ADA activity 
than the non TB causes of effusion .They obtained these results from a 
study of 359 patients with  TB effusion and TBM . They conclude that cut-
off levels 30 IU/L in effusions and 6 IU/L in the CSF indicate the probable 
diagnosis of  tuberculosis. 
In our study we conclude that a cut-off of 12 IU/L gives optimal 
sensitivity with high specificity and positive predictive values. (90.7 ,83.33 
and 95.12 respectively).  A comparison was done only in the culture 
positive TBM patients with the patients with known non –TBM group at a 
cut – off level of 12 IU/L. in this the sensitivity   
Drawback of this study : 
The good response to ATT in some of our culture negative patients in the 
TBM group could  partially be attributed to the presence of steroids in the 
treatment regimen. The CSF was inoculated in the LJ media and the 
sensitivity of culture could have been increased with the used of liquid 
media (Eg: BACTEC or MGIT). Only one CSF sample was used for 
inoculation. 
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CONCLUSION 
1. Tuberculosis of the central nervous system is the most common 
cause of chronic meningitis. 
2. Increased ADA activity in the CSF is a reliable indicator of TBM. 
3. A Cut-off of 12 IU/L gives a sensitivity , specificity , positive 
predicitive value and a negative predictive value of 90.7 ,83.33 , 
95.12 and 71.43 respectively  
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ABSTRACT: 
Background: Tuberculosis affection of the central nervous system is seen 
in 1 % all cases of tuberculosis. It’s a major extra-pulmonary manifestation 
of Tuberculosis.CNS TB is a devastating disease and the yield of AFB 
staining , CSF culture for MTB is low. The CSF – ADA levels have been 
found to be a good indirect evidence to the presence of TBM. 
Methods:  A total of 55 patients suffering from clinical features suggestive 
of sub-acute / chronic meningitis were included in this study and they were 
divided into TBM ( 43 patients ) and non TBM group ( 12 patients ) based 
on their CSF analysis , neuro – radiological imaging and response to 
treatment. The CSF – ADA level activity in both the groups was analysed. 
Results: A Cut-off of 12 IU/L gives a sensitivity , specificity , positive 
predicitive value and a negative predictive value of 90.7 ,83.33 , 95.12 and 
71.43 respectively. 
Conclusion:  ADA at a cut-off of 12 IU/L can be a reliable and rapid 
indirect indicator of TBM.    
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                                                   PROFORMA 
A Study on CSF Adenosine Deaminase levels as a marker of CNS   
Tuberculosis in 50 patients  
 
 
Serial.no:                                         
 Name:                                                      Age;                                          
sex: 
Height:                                                   weight:                                           
BMI 
Occupation:                                                   socio economic status: 
Presenting complaints:  
 
H/o presenting complaints: 
 
Past history: 
Tuberculosis: 
Bronchial Asthma: 
Diabetes Mellitus: 
Hypertension: 
Cancers; 
Ischemic Heart Disease: 
Liver Disorders; 
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Renal Disorders: 
Transfusions: 
HIV 
personal history: 
Smoking: 
No. Of Packs/Day                                       Duration: 
Any Other Tobacco Use: 
Alcoholism: 
Any Other Substance Abuse: 
Family history: 
 
EXAMINATION: 
General examination: 
Pallor: 
Icterus: 
Cyanosis: 
Clubbing: 
Pedal Edema: 
Lymph Node Enlargement; 
Pupil 
External marker of TB 
CNS: 
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Higher functions 
Cranial Nerves 
Motor 
Sensory 
Cerebellar 
Neck stiffness 
Spine , skull  
 
RESPIRATORY SYSTEM: 
 
CARDIOVASCULAR SYSTEM: 
 
ABDOMEN 
 
INVESTIGATIONS: 
Complete Hemogram: 
Haemoglobin: 
Total Count:                          
Differential Count: 
Hematocrit; 
MCV;                         MCHC:                         MCH 
Reticulocyte Count: 
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Platelet Count; 
CSF ANALYSIS 
Appearance 
Colour 
Protein 
Pressure 
Sugar 
Cells 
Cytology 
Grams stain 
AFB stain 
Culture ( bacterial) 
Culture (L-J medium for  TB) 
ADA levels 
CHEST XRAY 
ECG 
 
CT BRAIN 
 
MRI BRAIN 
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